Annexins (ANXs) are a family of calcium dependent phospholipid binding proteins. Phospholipids such as phosphatidylserine are rapidly exposed on the surfaces of injured endothelial cells, activated platelets, and apoptotic cells in a large number of disorders. In this study, annexin V and XI (ANXV and ANXXI) were individually fused to the C-terminal of staphylokinase (SAK), a fibrin-selective thrombolytic protein, to form chimeras for evaluation of their in-vitro thrombolytic activities. The two chimeras were found to have plasminogen activation activity of comparable efficiency. When the chimeras were challenged under higher concentrations of plasmin for 1 h, hydrolysis of them into moieties was not seen on SDS-PAGE. In two thrombolytic assays, SAK-ANXXI was found to resolve both platelet rich plasma (PRP) clots and platelet poor plasma (PPP) clots with an efficiency similar to that of SAK. However, SAK-ANXV showed significantly reduced efficiency. With regard to anticoagulation ability, SAK-ANXXI was also found to have a stronger effect on dose-dependent extension of clotting time among the four tested proteins. The unique long N-terminal tail of ANXXI, composed of 202 residues, in contrast to the 16 residues of ANXV, probably served successfully to dispatch two moieties to function properly in a complicated microenvironment. Hence, a new option other than the most committed ANXV for the ANX based chimera without elaboration of linker construction is presented.
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Key words: annexin; chimera; staphylokinase; thrombolytic Acute myocardial infarction and ischemic strokes are still the two leading causes of death in the modern world. 1, 2) Thrombolytic therapy has been an important treatment for myocardial infarction as well as ischemic strokes over the last decade, 2) however, the available thrombolytic agents have certain limitations, [3] [4] [5] such as unexpected bleeding due to systemic exhaustion ofantiplasmin and other clotting components. The resistance of secondary clots, which are rich in platelets, to the effect of plasminogen activators is another concern. 1, 6) This has led to many efforts to improve the potency and safety of thrombolytic agents. 5, 7, 8) Following injury to the endothelium and vessel wall, platelets adhere rapidly to the sub-endothelial matrix, then become activated and form the primary hemostatic plug. 9, 10) In the meanwhile, phospholipids such as phosphatidylserine (PS) are rapidly exposed on the membrane surfaces of activated platelets. [11] [12] [13] [14] The activated platelets provide anionic surfaces for the assembly and catalysis of intrinsic tenase (VIIIa/IXa), prothrombinase (Va/Xa), and XIa complexes, leading to explosive generation of thrombin and consolidation of the fibrin-platelet plug. [15] [16] [17] Thus, rapid exposure of PS on the cell surfaces of platelets is the key thrombogenic stimulus initiating and propagating the clotting cascade. 9, 10, 17) Annexins (ANXs) are a family of calcium-dependent phospholipid binding proteins. 18, 19) Structurally, ANXs are characterized by a highly -helical and tightly packed protein core domain of four to eight conserved repeats plus the N-terminal region, which is variable both in length and in sequence. 20, 21) It has been found * These two authors contributed equally to this article. y To whom correspondence should be addressed. Tel/Fax: +886-2-87924857; E-mail: cys@ndmctsgh.edu.tw Abbreviations: ANX, annexin; PS, phosphatidylserine; PRP, platelet rich plasma; PPP, platelet poor plasma; SAK, staphylokinase; tPA, tissue plasminogen activator that a stimulated platelet can contain nearly 200,000 annexin V (ANXV) binding sites, while this is minimal in quiescent status. 22) In contrast, only about 25,000 glycoprotein IIb/IIIa on an activated platelet can be bound by antibodies. [23] [24] [25] The most studied member of the ANXs is ANXV. ANXV, with a high affinity constant of 7 nM binding to PS, has been utilized in tracing apoptotic cells and activated platelets. [26] [27] [28] [29] Many efforts have been made to construct ANXV based chimeras for evaluation of their targeting effect at a potential thrombus. 6, 10, 30, 31) Staphylokinase (SAK) is one of the promising blood clot dissolving agents. 1, 6, [32] [33] [34] Although the thrombolytic potency of SAK has been found to be comparable to that of tPA, clinical trials have indicated that SAK has a superior fibrin specificity. 1, 35, 36) Hence, SAK has been chosen as the clot dissolving component in several chimeras. 6, 37, 38) Although a chimera composed of SAK and an ANX might exert both fibrin selective plasminogen activation and platelet targeting anticoagulation, no such chimera lacking a linker in-between has been investigated so far.
Annexin XI (ANXXI) has an unique long N-terminal tail composed of more than 202 amino acids, in contrast to the16 residues of the N-terminal tail of ANXV. 39) Only limited studies of the structure and function of ANXXI have been reported. 40) It was postulated that the long N-terminal tail of ANXXI might be able to function as a natural linker to segregate moieties of ANXXIbased chimeras. Here we report the preparation of two chimeras, SAK-ANXV and SAK-ANXXI, without an inserted linker, and evaluation of their in vitro thrombolytic related activities. It was found that SAK-ANXXI preserved good in vitro thrombolytic activity and had a better anticoagulation effect at low doses.
Materials and Methods
Gene cloning and construction of expression vectors. The coding region (411 bps) of the SAK gene of Staphylococcus aureus subsp. aureus N315, listed as A17531 at the NCBI web site, plus sequences for restriction by Nde I and XhoI, was chemically synthesized and provided by MDBio, Inc., Taipei, Taiwan. The synthesized DNA product was inserted into the NdeI and XhoI sites of pET24a(+) (Novagen, Madison, WI) to afford pET24-SAK, which was then transformed into JM109 following the standard molecular biology method. The right clone was selected by gene sequencing.
Genes of ANXV and ANXXI were cloned from MOLT-4 cells, a human T-cell leukemia cell line. RNA was isolated using Trizole (Invitrogen, Carlsbad, CA) following the manufacturer's manual. cDNAs were acquired by reverse transcription and amplification using the SuperscriptÔ II RT-PCR system (Invitrogen), following the manufacturer's manual. The primers used for ANXV were sense 5 0 -GGAATTCCATATGGCA-CAGGTTCTCAGA-3 0 and antisense 5 0 -CCGCTCGAG-GTCATCTTCTCCACAGAG-3 0 ; the primers for ANX-XI were sense 5 0 -GGAATTCCATATGAGCTACCCT-GGCTAT and antisense 5 0 -CCGCTCGAGGTCATTG-CCACCACAGAT. The NdeI and XhoI sites (underlined) were incorporated into the sense and antisense primers respectively for both cDNAs. The PCR products were inserted into the NdeI and XhoI sites of pET24a(+) to afford pET24-ANXV and pET24-ANXXI. By gene sequencing, the inserted genes were confirmed to be identical to that of the ANXV cDNA listed as NM001154 (GI:4809273) and that of the ANXXI cDNA listed as NM145869 (GI:22165432) at the NCBI web site.
PCR was performed on pET24-SAK to introduce the NdeI site (underlined) at the 5 0 and 3 0 ends of the SAK gene with platinum Taq DNA polymerase (Invitrogen) using sense primer 5 0 -GGAATTCCATATGTCAAGT-TCATTCGAC-3 0 and antisense primer 5 0 -GGAATTC-CATATGTTTCTTTTCTATAAC-3 0 . The PCR product was inserted into the NdeI site of pET24-ANXV to afford pET24-SAK-ANXV or of pET24-ANXXI to afford pET24-SAK-ANXXI. The direction of the inserted SAK and its sequence were confirmed by gene sequencing.
Expression and purification of SAK and chimeras.
The genes inserted in pET24a(+) were expressed using BL21 (DE3) in 100 ml LB. Induction was performed by the addition of IPTG (1 mM) at 37 C for 3 h. Cell lysis was carried out in lysis buffer (containing lysozyme 1 mg/ml) by ultrasonication. Purification of the expressed protein was conducted using a Ni-NTA affinity column (Qiagene, Hilden, Germany) following the manufacturer's manual. The buffer used for lysing BL21 and for washing the NTA column contained sodium phosphate (50 mM, pH 8.0), sodium chloride (300 mM), Triton X-100 (0.1%), mercaptoethanol (20 mM), imidazole (10 mM) and glycerol (10%). The desired protein was eluted using 250 mM imidazole in the above lysis buffer. The eluted protein solutions were stored in À20 C. The purified protein was diluted to the desired concentration in HBS before it was used for clot lysis assay. Protein assay was done as described by Bradford. 41) Concentration determinations were referred to a standard curve established using bovine serum albumin (66 kD).
Plasminogen activation reaction. To monitor the activation of plasminogen activity of fractions during purification of the expressed protein, 38, 42) a reaction mixture containing 1 mM human plasminogen (Chromogenix, Milano, Italy), and the protein fraction (3 nM) in 100 mM Tris-HCl, pH 7.5, was incubated at 37 C. At 2, 4, and 6 min, 5-ml aliquots were removed and diluted with 35 ml of buffer (700 mM NaCl, 100 mM Tris-HCl, pH 7.5). 38) When all of the aliquots had been collected, the chromogenic substrate N-p-tosyl-Gly-Pro-Lys nitroanilide (Chromogenix) was added to a final concentration of 1 mM. Cleavage of the substrate by the plasmin produced was monitored using a plate reader (Sunrise, Tecan, Austria) by measuring the increase in absorbance at 405 nm over a 10-min period at room temperature. Plasmin activity (represented by the increase in absorbance at 405 nm per min) was plotted versus the activation time.
For kinetic analysis, 35, 43, 44) an equimolar mixture of a chimera and plasminogen (approximate final concentration, 5 mM) with a 5% excess of plasminogen were incubated at 37 C for 10 min in 0.1 M sodium phosphate, pH 7.4, containing 25% glycerol; the mixture were then stored on ice. The preformed equimolar complex (final concentration, 5 nM) was incubated with plasminogen (2-48 mM for SAK-ANXV, 1-32 mM for SAK-ANXXI, 1-24 mM for SAK) at 37 C in 0.1 M sodium phosphate, pH 7.4. The plasmin generated was measured at different time intervals (0-5 min) with S-2251 (final concentration, 1 mM) after 30-fold dilution in 0.1 M sodium phosphate containing 0.1 M NaCl. Initial activation rates were obtained from plots of the concentration of generated plasmin versus time.
Clot lysis assays. Citrated platelet rich plasma (PRP) from healthy donors was provided by Tri-Service General Hospital, Taipei, Taiwan. Platelet pool plasma (PPP) was prepared by centrifugation of PRP at 5;000 Â g for 5 min. Once prepared, PPP was stored at 4 C. All plasma was used within one week of blood collection. Clotting was initiated by adding human thrombin (0.8 NIH units/ml, Sigma, St. Louis, MI) and CaCl 2 (20 mM) in Hepes-buffered saline (HBS, 20 mM HEPES, 130 mM NaCl, pH 7.4). Immediately after mixing, aliquots of 100 ml of the clotting mixture were transferred to the wells of a microtiter plate and incubated for 2 h at room temperature to form PRP and PPP clots. Clot lysis assays were performed at room temperature by the addition of the tested protein at 200 nM and human plasminogen (1 mM) in HBS-CaCl 2 (100 ml). Clot lysis as reflected by reduction in turbidity was monitored using a microtiter plate reader at 405 nm. The solution on top of the PRP clot was displaced before measurement of the OD value and in-placed afterward for further lysis reaction. The percentage of remaining turbidity was plotted over time. Separately, clots were treated with the tested protein (500 nM) in HBS-CaCl 2 with no added plasminogen for 1 h. The protein solution was removed, and each clot was washed twice with HBS (100 ml). Then plasminogen (1 mM) in HBS-CaCl 2 (100 ml) was added for incubation at 37 C. All the controls were done as tests except for the addition of the tested protein. Variations in turbidity were also monitored following the addition of thrombin (0.8 NIH units/ ml) to the above clotting mixture containing the tested protein at a final concentration of 100, 150, or 200 nM.
Clotting time. A mechanical coagulometer (ST-4; Diagnostica Stago, Parsippany, NJ) was used to monitoring clotting time following the addition of human PRP (120 ml, 3.2% citrated) to a mixture to form a solution of 150 ml containing various concentrations of the tested proteins (50, 100, 150, and 200 nM), thrombin (2 NIH units/ml), and CaCl 2 (20 mM) in HBS, pH 7.4.
Stability of chimeras against action of plasmin.
To determine the stability of the fusion protein in the presence of plasmin, the method of Ueshima et al., used to process SAK derivatives, was adopted and modified as follows. 45 ) Equimolar mixtures of plasminogen and a chimera at 6 mM were incubated in Tris-HCl, (100 mM, pH 7.5) at 37 C for various periods for about 1 h. They were incubated for 8 min when SAK was used in place of a chimera. The processed mixture was incubated with an equal volume of 2 Â sample loading buffer containing DTT (0.5 mM) for 5 min in an ice bath. Then it was loaded on a sodium dodecyl sulfate-16% polyacrylamide gel, and separated at 100 V for 190 min.
Results and Discussion
All the expressed proteins contained a 6-His-tag at the C-terminal and were purified to high purity as shown on SDS-PAGE (Fig. 1 ) using a Ni-NTA column. The concentrated protein, eluted with buffer containing Triton X-100 (0.1%) and glycerol (10%), remained soluble for about 6 months otherwise tended to precipitate after a few days. The arrangement to fuse SAK at the N-terminal of the ANXs was to avoid cleavage of chimeras around the fusion site since plasmin tends to attack around sequences within the first 10 N-terminal residues of SAK. 38) Also, the first 10 N-terminal residues of staphylokinase must be removed with plasmin to expose the positively charged lysine residue at position 11, which is essential for the plasminogen activation activity of SAK. 38, 41, [46] [47] [48] Plasminogen activation assay was routinely used to monitor active fractions during the expression of the expressed His-tagged proteins, in which amidolytic activity on the chromogenic peptide substrate of plasmin which was generated in the presence of a catalytic amount of the tested protein was measured. Both chimeras were found to be virtually void of amidolytic activity in the absence of plasminogen. Kinetic analysis of chimeras afforded comparable catalytic efficiency (k cat =K m ) of 0.019 mM À1 S À1 for SAK-ANXV and 0.020
for SAK-ANXXI, in comparison with 0.028
for SAK (mean of two independent determinations with R > 0:99, 0.97, and 0.99 respectively). The liability of chimera to hydrolysis was checked by challenge under equimolar reaction of plasminogen and chimera at 6 mM. 38) We found that it is difficult to see both SAK and a clear separation of the formed plasmin from the remaining plasminogen under the non-reducing condition in the same gel of SDS-PAGE (data not shown). For clear separation (Fig. 1) , DTT was applied to cleave the -chain (29 kD) of plasmin. 38) It was found that most plasminogen was converted into plasmin in about 10 min by either chimera, as seen in Fig. 1 . In contrast, over 1 h of reaction, no hydrolysis of either chimera into the corresponding moiety, e.g., SAK, ANXV, or ANXXI, was seen on the gel. Hence, the observed plasminogen activation activities of chimeras are believed to derive mainly from the action of chimeras, not from that of the suspected hydrolysis product SAK. Similarly, most plasminogen was converted into plasmin in 10 min by reaction with SAK (Fig. 1A, lane 11) under the same equimolar condition. The reported structure of SAK indicated that both the Nterminus and the C-terminus were directed away from the protein core. 49) This arrangement might explain why extension of the protein sequence of SAK was tolerated.
After several attempts, clot lysis assay run at 200 nM for convenience of comparison though SAK at a lower dose (75 nM) for test has been reported. 6) It was found that both chimeras preserved the clot lysis activity to different extent (Fig. 2) . SAK-ANXXI exhibited better efficiency in hydrolyzing PPP and PRP clots though it was a bit less efficient than SAK. Clot lysis by SAK-ANXV was apparently inefficient. It has been reported that it is the surface assembly of the thin layer complex of clot fibrin . plasma plasmin(ogen) . SAK following distribution of plasma plasminogen to exert the most capability of clot lysis activity plus that derived from plasmin produced by the interaction of plasminogen and SAK in bulky solution above the clot. 36, 50) As shown in Fig. 3 , the protein tested was allowed to pre-incubate with clots without plasmin(ogen) for 1 h, then the unbound protein was removed and plasminogen was added for further incubation. As reported, a plasminogen activator like SAK does not specifically bind to and lyses clot without the involvement of plasminogen. Only in the case of SAK and SAK-ANXXI up to 500 nM, residual clot lysis activity was seen and the clot lasted much longer than that shown in Fig. 2 . Nearly absence of activity was seen for SAK-ANXV. The residual clot lysis activity probably derived from sparse binding of the SAK moiety to plasminogen bound inside when the clot was formed from plasma. It appears likely that the effect of the ANX moiety of a chimera works better to compete against the formation of a PRP clot than to resolve the formed clot. Hence, further comparison was carried out based on anticoagulation activity. The variation in turbidity of the clotting mixture containing SAK or a chimera after the addition of thrombin was monitored. A typical set of data is presented in Fig. 4 . The variation in turbidity reflected by the OD value indicates that a clot was forming and lysing although it might not have been concrete enough to be detected using a tip. A distinct variation pattern of turbidity during clot formation was found among chimeras and SAK, probably indicating an integral effect of the unhydrolyzed chimera. In the case of SAK (Fig. 4A) , a clot apparently formed. The formed clot was soon lysed. The OD value (turbidity) varied accordingly. In the case of SAK-ANXXI (Fig. 4B) , it was apparent that PRP clot formation was retarded at 100 nM since no sound gel type polymer but at most viscous liquid was seen (discerned using a tip). The later increase in the OD value was probably caused by slow formation of a small white aggregate of unknown components in the center of the well, followed by fast movement of it aside to the well wall, resulting in a steep drop in the OD value. In the case of SAK-ANXV at 200 nM (Fig. 4C) , PRP clot formation was a bit similar to the case of SAK-ANXXI. At a lower concentration of 150 nM or 100 nM, a clot was formed and was not resolved within the measuring period. Furthermore, a mechanical coagulometer was applied to determine dose-dependent effect on extension of clotting time (Fig. 5) . 31) For convenience, thrombin was increased to 2 NIH units per ml. ANXXI were A platelet rich plasma clot was treated with a solution containing the thrombolytic protein at 500 nM and CaCl 2 (20 mM) in HBS (SAK, white circle; SAK-ANXV, white triangle; SAK-ANXXI, black square) or the same solution without the protein as a control for clot stability (diamond) for 1 h. Then the solution was removed and the clot was washed twice with HBS, followed by the addition of a solution containing plasminogen (1 mM) and CaCl 2 (20 mM) in HBS. A set of representative results of three independent experiments is presented here.
found to have a stronger effect on the extension of clotting time than ANXV. Chimeras were found to have a stronger effect than unfused ANXs. It is apparent that SAK-ANXXI had a much stronger effect than the other three proteins tested. SAK did not have a dose-dependent effect (data not shown) probably due to lysis of the clot at a higher dose when it was forming, as shown in Fig. 4A .
Interaction between plasmin(ogen) and SAK can be various depending on the presence and status of fibrin. 35, 51) It has been reported that SAK has much weaker affinity to plasminogen in the absence of fibrin, i.e., plasminogen activation assay and SAK has the strongest affinity to partially degraded fibrin bound plasmin(ogen) when fibrinolysis has just begun. 50 ) SAK tends to undergo surface assembly of a thin layer complex with fibrin bound plasma plasmin(ogen) on the clot. It is known that ANX protein tends to polymerize on anionic membrane surfaces, 52) thus making the anionic phospholipids unavailable for assembly of coagulation enzyme complexes on platelets. 53, 54) Whether the ANX moiety after it is fused with SAK can still polymerize to the highest degree on activated platelets and in the meanwhile whether the fused SAK moiety can interact properly with partially degraded fibrin bound plasmin(ogen) is a major concern in the application of an ANX chimera. It was postulated that the long N-terminal sequence of ANXXI probably serves as a natural linker to dispatch two moieties to function properly in a complicated microenvironment when they are still linked. Thus, a new option other than the most committed ANXV and without the need for elaborate work on construction of the complicated linker when one considers the ANX based chimera for a good targeting effect at activated platelets or apoptotic cells is presented here. 
